Get the Stockscreener App
701.42
0.80%
-5.64
After Hours:
702.10
0.68
+0.10%
Regeneron Pharmaceuticals Inc stock is traded at $701.42, with a volume of 728.88K.
It is down -0.80% in the last 24 hours and down -9.76% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$707.06
Open:
$703.02
24h Volume:
728.88K
Relative Volume:
1.03
Market Cap:
$73.54B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
17.09
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
-6.67%
1M Performance:
-9.76%
6M Performance:
+7.61%
1Y Performance:
+18.88%
1-Day Range:
$700.26
$714.48
1-Week Range:
$668.85
$756.40
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
PKO Investment Management Joint Stock Co Has $3.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strs Ohio Sells 2,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fifth Third Bancorp Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MSN
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth - Insider Monkey
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing? - The Globe and Mail
Del Sette Capital Management LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Weakness - simplywall.st
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $995.00 - MarketBeat
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - BioPharma Dive
Wealthfront Advisers LLC Purchases 2,202 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
State of New Jersey Common Pension Fund D Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Danske Bank A S Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Presses Amgen for Eylea Antitrust Damages Evidence - Bloomberg Law News
Royal Bank Of Canada Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings - Benzinga
REGN Maintained by Barclays -- Price Target Lowered to $917 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $917.00 Price Target at Barclays - MarketBeat
Barclays Adjusts Regeneron Pharmaceuticals Price Target to $917 From $923 - marketscreener.com
Bernstein Adjusts Regeneron Pharmaceuticals PT to $916 From $913 - marketscreener.com
Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $796.00 - MarketBeat
REGN Maintains by Truist Securities -- Price Target Lowered to $796 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $800.00 Price Target at Wells Fargo & Company - MarketBeat
RBC Trims Price Target on Regeneron Pharmaceuticals to $762 From $779, Keeps Sector Perform Rating - marketscreener.com
REGN Maintained by Wells Fargo -- Price Target Lowered to $800 - GuruFocus
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mcdonald Capital Investors Inc. CA - MarketBeat
Regeneron achieves 1st-qtr 2026 double-digit growth - The Pharma Letter
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Regeneron Q1 2026 net income falls 10% to $727m - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call Highl - GuruFocus
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
REGN SWOT Analysis: Financial Strength and Growth Opportunities Revealed in 10-Q Filing - GuruFocus
3 Healthcare Stocks We Keep Off Our Radar - The Globe and Mail
Research Alert: CFRA Retains Buy Rating On Shares Of Regeneron Pharmaceuticals, Inc. - Moomoo
Why (REGN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Regeneron Pharmaceuticals (REGN) Margins Hold Near 31% Challenging Bearish Profitability Narratives - simplywall.st
Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU - MSN
Regeneron wins FDA approval for hearing loss therapy - MSN
Truist cuts Regeneron stock price target on FDA approval delay By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Plans $0.94 Quarterly Dividend - MarketBeat
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's
Regeneron Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results - MarketBeat
Why Regeneron (REGN) Shares Are Getting Obliterated Today - TradingView
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 7.8%Here's What Happened - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RYAN ARTHUR F | Director |
Mar 02 '26 |
Sale |
785.50 |
100 |
78,550 |
17,703 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Option Exercise |
376.69 |
1,638 |
617,018 |
3,341 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Sale |
781.33 |
1,638 |
1,279,812 |
1,703 |
0.23%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):